Home › Brands › Tilray Portugal
⚐ Flag an error How this page was made
Also known as: Tilray Cantanhede · Tilray Portugal Cantanhede

Tilray Portugal

Medical cannabis producer and subsidiary of Tilray Brands operating in Portugal.

Automated fact-check pass
5 cited sources
Published
Last reviewed
How this page was made
↯ The honest take

Tilray Portugal is a documented medical cannabis cultivation and processing facility licensed by INFARMED, Portugal's medicines regulator. It operates as a B2B supplier to EU pharmacies and distributors, not a consumer brand. 'EU-GMP certified' is a regulatory baseline, not a quality award. Claims about being 'first' or 'largest' should be checked against current dates and independent sources, not company marketing.

What we could verify

Tilray Portugal is a medical cannabis cultivation, extraction, and processing facility located in Cantanhede, Coimbra region, Portugal. It operates under licensing from INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde), Portugal's national medicines regulator, which authorises cultivation, manufacture, and export of cannabis-based medicines under Decree-Law 8/2019 [1]. The site is owned and operated by a Portuguese subsidiary of Tilray Brands, Inc., a Canadian public company traded on NASDAQ and TSX under ticker TLRY [2]. Tilray Brands was formed in 2021 through the merger of Tilray, Inc. and Aphria Inc.; reporting indicates the Portuguese operation was originally built by Tilray, Inc. and announced in 2016–2017, though exact pre-merger dating is not consistently documented across public sources [3]. The facility combines indoor and greenhouse cultivation with on-site processing and is used to supply licensed importers, pharmacies, and distributors in EU medical cannabis markets [2]. Strong evidence

What 'Tilray Portugal' as a brand name does and does not tell you

Cannabis strain and product names in the market often do not reliably indicate actual breeder, origin, or consistency [4]. A product labelled 'Tilray Portugal' indicates that the cannabis was produced or processed at the Cantanhede facility and is distributed by Tilray Brands, but it does not tell you the cultivar name, THC/CBD levels, terpene profile, or whether the product is the same across batches or countries. Cannabis flower and extracts are not pharmaceuticals with fixed formulations; cannabinoid content and effects vary by harvest, growing conditions, and processing method. The term 'Portugal' in a product name is geographic labelling, not a quality marker. Weak / limited

What to check if you see Tilray Portugal products for sale

If a healthcare provider prescribes or a pharmacy offers a product labelled as Tilray Portugal, verify the following before using it:

  1. Certificate of Analysis (CoA): Any medical cannabis product sold in an EU country should have a batch-specific lab report showing cannabinoid content (THC, CBD), residual solvents, pesticides, microbial limits, and heavy metals. Check the lab name, test date, and batch number on the product label, and request the full CoA from the pharmacy [5].
  1. Current INFARMED licensing: Confirm that Tilray's Portuguese subsidiary currently holds a valid INFARMED cultivation and manufacturing licence by checking the official INFARMED licensed operators list.
  1. Country-specific registration: Different EU countries have different import and approval processes. If buying in Germany, Poland, the Czech Republic, or another EU market, ask your pharmacist or regulator (e.g. BfArM in Germany) whether that specific SKU is registered and approved for supply in that country [2].
  1. Prescriber guidance: Only use cannabis-based medicines as prescribed by a physician familiar with your medical history. 'Medical' does not mean safe for everyone; cannabis has documented interactions and contraindications.

Do not rely on company websites, retailer claims about 'premium,' 'first,' 'largest,' or 'best' as primary evidence. Marketing claims about EU-GMP or facility achievements should be cross-checked against regulatory databases and independent journalism Strong evidence.

EU-GMP status and regulatory context

EU-GMP (Good Manufacturing Practice) is a baseline regulatory requirement for manufacturing medicinal products in the EU, audited by national competent authorities and the European Medicines Agency [5]. It is not a voluntary award or a mark of premium quality; it is a legal requirement. Tilray Brands has described the Cantanhede facility as holding EU-GMP certification [2], which is necessary to legally operate. However, marketing language that frames EU-GMP as a distinctive achievement should be read cautiously: many other cannabis producers in Portugal, Germany, Denmark, and Malta also hold EU-GMP status. Claims that a facility was 'one of the first' or 'the largest' in the EU should be checked against current sources and dated carefully, as the EU cannabis cultivation sector has expanded significantly since 2016–2017. Disputed

Cannabis produced at Tilray Portugal is licensed only for medical use under prescription in jurisdictions that permit medical cannabis imports [1]. Portugal itself does not have a regulated adult-use market; domestic medical cannabis is dispensed through pharmacies under strict INFARMED control and is available to a limited patient population. Export to other EU member states depends on each country's import authorisations, pharmacy stocking, prescriber willingness, and whether a physician judges cannabis-based medicines appropriate for a given patient. Availability and access vary widely by country and change frequently. Do not assume that a product available in one EU country is available in another. Strong evidence

What Weedpedia could not confirm

Weedpedia could not independently verify specific product lineages, strain names, cannabinoid ranges, terpene profiles, or branded SKUs attributed to Tilray Portugal. Cannabis product naming is not standardised across markets, and strains are not reliably reproducible [4]. Any claim about a specific 'Tilray Portugal' product's effects, potency, or origin should come from a current Certificate of Analysis and your prescriber, not from a company website or retailer. If you have documentary evidence (official licensing records, batch test reports, company filings) about Tilray Portugal that contradicts or clarifies this profile, please flag an error so we can update it. No data

Sources

  1. Government Assembleia da República. Lei n.º 33/2018 e Decreto-Lei n.º 8/2019 — Utilização de medicamentos, preparações e substâncias à base da planta cannabis para fins medicinais. Diário da República, Portugal.
  2. Government Tilray Brands, Inc. Annual Report on Form 10-K, fiscal year 2023, filed with the U.S. Securities and Exchange Commission, including disclosures of EU subsidiaries and Portuguese operations.
  3. Reported Reuters. Tilray to build medical marijuana facility in Portugal. 2017.
  4. Peer-reviewed Piomelli, D., Russo, E. B. (2016). The Cannabis sativa versus Cannabis indica debate: An interview with Ethan Russo, MD. Cannabis and Cannabinoid Research, 1(1), 44–46.
  5. Government European Medicines Agency. Good manufacturing practice guidance and EudraGMDP database of GMP certificates.

How this page was made

Generation history

Oct 31, 2026
Fact-check pass — raised 7 flags
Oct 31, 2026
Revision
Jun 8, 2026
Fact-check pass — raised 2 flags
Jun 8, 2026
Initial draft

Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.